Restoration of tissue factor pathway inhibitor inhibits invasion and tumor growth in vitro and in vivo in a malignant meningioma cell line

International Journal of Oncology

Volumn 29, Issue 1, 2006, Pages 25-32

  Kondraganti, Shakuntala ^a   Gondi, Christopher S ^a   Gujrati, Meena ^a   McCutcheon, Ian ^b   Dinh, Dzung H ^a   Rao, Jasti S ^a   Olivero, William C ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Angiogenesis; Invasion; TFPI 2

Indexed keywords

CASPASE 3; COLLAGEN; CYTOCHROME C; GLYCOPROTEIN; LAMININ; LIPOPROTEIN; LIPOPROTEIN-ASSOCIATED COAGULATION INHIBITOR; MATRIGEL; PLACENTA PROTEIN 5; PROTEIN BAX; PROTEOGLYCAN; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE-FACTOR-PATHWAY INHIBITOR 2;

ANIMAL; ARTICLE; BIOSYNTHESIS; CANCER TRANSPLANTATION; CELL MOTION; COCULTURE; CYTOLOGY; DRUG COMBINATION; ENDOTHELIUM CELL; FEMALE; GENETIC TRANSFECTION; GENETICS; HUMAN; MENINGIOMA; METABOLISM; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; SKIN; TUMOR CELL LINE; VASCULARIZATION;

ANIMALS; BCL-2-ASSOCIATED X PROTEIN; CASPASE 3; CELL LINE, TUMOR; CELL MOVEMENT; COCULTURE TECHNIQUES; COLLAGEN; CYTOCHROMES C; DRUG COMBINATIONS; ENDOTHELIAL CELLS; FEMALE; GLYCOPROTEINS; HUMANS; LAMININ; LIPOPROTEINS; MENINGEAL NEOPLASMS; MENINGIOMA; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PROTEOGLYCANS; SKIN; TRANSFECTION;

EID: 33750630284     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.29.1.25     Document Type: Article

References (39)

1. Miyagi Y, Koshikawa N, Yasumitsu H, Miyagi E, Hirahara F, Aoki I, Misugi K, Umeda M and Miyazaki K: cDNA cloning and mRNA expression of a serine proteinase inhibitor secreted by cancer cells: identification as placental protein 5 and tissue factor pathway inhibitor-2. J Biochem 116: 939-942, 1994.
2. Rao CN, Cook B, Liu Y, Chilukuri K, Stack MS, Foster DC, Kisiel W and Woodley DT: HT-1080 fibrosarcoma cell matrix degradation and invasion are inhibited by the matrix-associated serine protease inhibitor TFPI-2/33 kDa MSPI. Int J Cancer 76: 749-756, 1998.
3. Sprecher CA, Kisiel W, Mathewes S and Foster DC: Molecular cloning, expression, and partial characterization of a second human tissue-factor-pathway inhibitor. Proc Natl Acad Sci USA 91: 3353-3357, 1994.
4. Petersen LC, Bjorn SE, Olsen OH, Nordfang O, Norris F and Norris K: Inhibitory properties of separate recombinant Kunitz-type-protease-inhibitor domains from tissue-factor-pathway inhibitor. Eur J Biochem 235: 310-316, 1996.
5. Rao CN, Liu YY, Peavey CL and Woodley DT: Novel extracellular matrix-associated serine proteinase inhibitors from human skin fibroblasts. Arch Biochem Biophys 317: 311-314, 1995.
6. Rao CN, Peavey CL, Liu YY, Lapiere JC and Woodley DT: Partial characterization of matrix-associated serine protease inhibitors from human skin cells. J Invest Dermatol 104: 379-383, 1995.
7. Rao CN, Gomez DE, Woodley DT and Thorgeirsson UP: Partial characterization of novel serine proteinase inhibitors from human umbilical vein endothelial cells. Arch Biochem Biophys 319: 55-62, 1995.
8. Udagawa K, Miyagi Y, Hirahara F, Miyagi E, Nagashima Y, Minaguchi H, Misugi K, Yasumitsu H and Miyazaki K: Specific expression of PP5/TFPI2 mRNA by syncytiotrophoblasts in human placenta as revealed by in situ hybridization. Placenta 19: 217-223, 1998.
9. Lino M, Foster DC and Kisiel W: Quantification and characterization of human endothelial cell-derived tissue factor pathway inhibitor-2. Arterioscler Thromb Vasc Biol 18: 40-46, 1998.
10. Liu Y, Stack SM, Lakka SS, Khan AJ, Woodley DT, Rao JS and Rao CN: Matrix localization of tissue factor pathway inhibitor-2/matrix-associated serine protease inhibitor (TFPI-2/MSPI) involves arginine-mediated ionic interactions with heparin and dermatan sulfate: heparin accelerates the activity of TFPI-2/MSPI toward plasmin. Arch Biochem Biophys 370: 112-118, 1999.
11. Miyagi Y, Yasumitsu H, Eki T, Miyata S, Kkawa N, Hirahara F, Aoki I, Misugi K and Miyazaki K: Assignment of the human PP5/TFPI-2 gene to 7q22 by FISH and PCR-based human/rodent cell hybrid mapping panel analysis. Genomics 35: 267-268, 1996. (Pubitemid 26236182)
12. Konduri SD, Rao CN, Chandrasekar N, Tasiou A, Mohanam S, Kin Y, Lakka SS, Dinh D, Olivero WC, Gujrati M, Foster DC, Kisiel W and Rao JS: A novel function of tissue factor pathway inhibitor-2 (TFPI-2) in human glioma invasion. Oncogene 20: 6938-6945, 2001.
13. Rao CN, Lakka SS, Kin Y, Konduri SD, Fuller GN, Mohanam S and Rao JS: Expression of tissue factor pathway inhibitor 2 inversely correlates during the progression of human gliomas. Clin Cancer Res 7: 570-576, 2001.
14. Lakka SS, Konduri SD, Mohanam S, Nicolson GL and Rao JS: In vitro modulation of human lung cancer cell line invasiveness by antisense cDNA of tissue factor pathway inhibitor-2. Clin Exp Metastasis 18: 239-244, 2000.
15. Konduri SD, Tasiou A, Chandrasekar N and Rao JS: Overexpression of tissue factor pathway inhibitor-2 (TFPI-2), decreases the invasiveness of prostate cancer cells in vitro. Int J Oncol 18: 127-131, 2001.
16. Akeyson EW and McCutcheon IE: Management of benign and aggressive intracranial meningiomas. Oncology (Williston Park) 10: 747-756, 1996.
17. Younis GA, Sawaya R, De Monte F, Hess KR, Albrecht S and Bruner JM: Aggressive meningeal tumors: review of a series. J Neurosurg 82: 17-27, 1995.
18. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685, 1970.
19. Towbin H, Staehelin T and Gordon J: Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 76: 4350-4354, 1979.
20. Go Y, Chintala SK, Mohanam S, Gokaslan Z, Venkaiah B, Bjerkvig R, Oka K, Nicolson GL, Sawaya R and Rao JS: Inhibition of in vivo tumorigenicity and invasiveness of a human glioblastoma cell line transfected with antisense uPAR vectors. Clin Exp Metastasis 15: 440-446, 1997.
21. Mohanam S, Sawaya R, McCutcheon I, Ali-Osman F, Boyd D and Rao JS: Modulation of in vitro invasion of human glioblastoma cells by urokinase-type plasminogen activator receptor antibody. Cancer Res 53: 4143-4147, 1993.
22. Miyazaki K, Hattori Y, Umenishi F, Yasumitsu H and Umeda M: Purification and characterization of extracellular matrix-degrading metalloproteinase, matrin (pump-1), secreted from human rectal carcinoma cell line. Cancer Res 50: 7758-7764, 1990.
23. Umenishi F, Yasumitsu H, Ashida Y, Yamauti J, Umeda M and Miyazaki K: Purification and properties of extracellular matrix-degrading metallo-proteinase overproduced by Rous sarcoma virus-transformed rat liver cell line, and its identification as transin. J Biochem 108: 537-543, 1990.
24. Koshikawa N, Yasumitsu H, Umeda M and Miyazaki K: Multiple secretion of matrix serine proteinases by human gastric carcinoma cell lines. Cancer Res 52: 5046-5053, 1992.
25. Jin M, Udagawa K, Miyagi E, Nakazawa T, Hirahara F, Yasumitsu H, Miyazaki K, Nagashima Y, Aoki I and Miyagi Y: Expression of serine proteinase inhibitor PP5/TFPI-2/MSPI decreases the invasive potential of human choriocarcinoma cells in vitro and in vivo. Gynecol Oncol 83: 325-333, 2001.
26. Folkman J: Antiangiogenic gene therapy. Proc Natl Acad Sci USA 95: 9064-9066, 1998.
27. Ollivier V, Bentolila S, Chabbat J, Hakim J and De Prost D: Tissue factor-dependent vascular endothelial growth factor production by human fibroblasts in response to activated factor VII. Blood 91: 2698-2703, 1998.
28. Taniguchi T, Kakkar AK, Tuddenham EG, Williamson RC and Lemoine NR: Enhanced expression of urokinase receptor induced through the tissue factor-factor VIIa pathway in human pancreatic cancer. Cancer Res 58: 4461-4467, 1998.
29. Hamada K, Kuratsu J, Saitoh Y, Takeshima H, Nishi T and Ushio Y: Expression of tissue factor correlates with grade of malignancy in human glioma. Cancer 77: 1877-1883, 1996.
30. Mueller BM, Reisfeld RA, Edgington TS and Ruf W: Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci USA 89: 11832-11836, 1992.
31. Nakagawa K, Zhang Y, Tsuji H, Yoshizumi M, Kasahara T, Nishimura H, Nawroth PP and Nakagawa M: The angiogenic effect of tissue factor on tumors and wounds. Semin Thromb Hemost 24: 207-210, 1998.
32. Hembrough TA, Ruiz JF, Papathanassiu AE, Green SJ and Strickland DK: Tissue factor pathway inhibitor inhibits endothelial cell proliferation via association with the very low density lipoprotein receptor. J Biol Chem 276: 12241-12248, 2001.
33. Tasiou A, Konduri SD, Yanamandra N, Dinh DH, Olivero WC, Gujrati M, Obeyesekere M and Rao JS: A novel role of tissue factor pathway inhibitor-2 in apoptosis of malignant human gliomas. Int J Oncol 19: 591-597, 2001.
34. Nicholson DW and Thornberry NA: Caspases: killer proteases. Trends Biochem Sci 22: 299-306, 1997.
35. Nagata S: Apoptosis by death factor. Cell 88: 355-365, 1997.
36. Kluck RM, Bossy-Wetzel E, Green DR and Newmeyer DD: The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 275: 1132-1136, 1997.
37. Eischen CM, Rehg JE, Korsmeyer SJ and Cleveland JL: Loss of Bax alters tumor spectrum and tumor numbers in ARF-deficient mice. Cancer Res 62: 2184-2191, 2002.
38. Isenmann S, Engel S, Gillardon F and Bahr M: Bax antisense oligonucleotides reduce axotomy-induced retinal ganglion cell death in vivo by reduction of Bax protein expression. Cell Death Differ 6: 673-682, 1999.
39. La Casse EC, Baird S, Korneluk RG and MacKenzie AE: The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 17: 3247-3259, 1998.